the aid library

Filter

10230

WHO Guideline on Country Pharmaceutical Pricing Policies

World Health Organization WHO World Health Organization (2020) C_WHO

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov ... more

Guidelines for malaria vector control
recommended

World Health Organization WHO (2019) C_WHO

Vector control is a vital component of malaria prevention, control and elimination strategies because it can be highly effective in providing personal protection and/or reducing disease transmission.

National Action Plan of the Islamic Republic of Iran for combating antimicrobial resistance

Ministry of Health and Medical Education Iran (2016) C_WHO

Antimicrobial resistance is one of the most important threats to the health worldwide. Antimicrobial resistance or drug resistance is the reduction of the pharmaceutical effects of a drug against a disease or reduction of its effectiveness in improv ... more

WHO operational handbook on tuberculosis: module 2: screening: systematic screening for tuberculosis disease

World Health Organization WHO (2020) C_WHO

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

India: TRAINING OF Link ART Centre (LAC) COUNSELLORS - HANDBOOK FOR TRAINEES

National AIDS Control Organization (NACO), Ministry of Health and Family Welfare, Government of India (2012) C1

Measles Elimination Field Guide

World Health Organization, Western Pacific Region (2013) C_WHO

Joint position paper on the provision of mobility devices in less resourced settings

World Health Organization; USAID (2011) C_WHO

A step towards implementation of the Convention on the Rights of Persons with Disabilities (CRPD) related to personal mobility.

Planning Guide for national implementation of the Global Strategy for Infant and Young Child Feeding

World Health Organization; UNICEF (2007) C_WHO

Diphtheria vaccine: WHO position paper – August 2017. Vaccin antidiphtérique: Note de synthèse de l’OMS – août 2017

World Health Organization WHO (2017) C_WHO

Weekly epidemiological record/ Relevé épidémiologique hebdomadaire 4 AUGUST 2017, 92th YEAR / 4 AOÛT 2017, 417-436

Medical device donations: considerations for solicitation and provision. Second edition

World Health Organization WHO (2024) CC

Medical devices are used for the prevention, diagnosis and treatment of illness and diseases and for rehabilitation. WHO developed guidance on medical device donation in 2011, which has been now reviewed, with new evidence, new references on considerations for medical device solicitation and provisi ... more

The National Medicines Policy Of Zimbabwe

Ministry of Health and Child Welfare, Zimbabwe (2011) C1

The best start in life. Breastfeeding for the prevention of noncommunicable diseases and the achievement of the Sustainable Development Goals in the WHO European Region

World Health OrganizationEurope (2020) C_WHO

Healthy maternal nutrition, exclusive breastfeeding, and optimal infant and young child nutrition are critical for appropriate growth and development, as well as reducing the risk of developing noncommunicable diseases (NCDs), for both mothers and children. On 7–8 November 2018 the WHO Regional Of ... more

Multiple first-line therapies as part of the response to antimalarial drug resistance

World Health Organization WHO (2024) C_WHO

Effective malaria case management requires quick access to diagnostics and antimalarial treatments to reduce illness and death. Artemisinin-based combination therapy (ACT) has been essential to malaria treatment since 2001, as it combines artemisinin for rapid parasite reduction with a partner drug ... more

Xpert MTB/RIF implementation manual

World Health Organization WHO (2014) C_WHO

Technical and operational ‘how-to’: practical considerations

World report on child injury prevention

World Health Organization (WHO), the United Nations Children’s Fund (UNICEF) Peden, Margie et al. (2008) C_WHO

Every year, around 830 000 children die from unintentional or "accidental" injuries. The vast majority of these injuries occur in low-income and middle-income countries. However, dozens of prevention strategies and programmes exist. If they were integrated into other child survival programmes and im ... more

Deafness and hearing loss - Fact sheet

World Health Organization (WHO) (2018) C_WHO

Updated March 2018 | Accessed Online March 2018